Biomarker signatures for progressive idiopathic pulmonary fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease in which circulatory biomarkers has the potential for guiding management in clinical practice. We assessed the prognostic role of serum biomarkers in three independent IPF cohorts, the Australian IPF Registry (AIPFR), Trent Lung Fibrosis (TLF) and Prospective Observation of Fibrosis in the Lung Clinical Endpoints (PROFILE).

Citation:
Clynick B, Corte TJ, Jo HE, Stewart I, Glaspole IN, ……. De Jong E, Cha L, Tan DBA et al. Biomarker signatures for progressive idiopathic pulmonary fibrosis. Eur Respir J. 2021:2101181.

Abstract:
Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease in which circulatory biomarkers has the potential for guiding management in clinical practice. We assessed the prognostic role of serum biomarkers in three independent IPF cohorts, the Australian IPF Registry (AIPFR), Trent Lung Fibrosis (TLF) and Prospective Observation of Fibrosis in the Lung Clinical Endpoints (PROFILE).